During the two years of the pandemic, there were sky-rocketing sales of Covid-19 portfolio of drugs, sometimes even severe shortages. But now the industry is saddled with a huge inventory of raw materials and medicines used in Covid-19, and staring at potential losses and write-offs running into hundreds of crores.
